A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 09 May 2016
At a glance
- Drugs AMG 357 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Amgen
- 05 May 2016 Status changed from recruiting to discontinued.
- 06 Nov 2015 Tablets in 15 count bottles changed to 20 count bottles as reported by ClinicalTrials.gov record.
- 04 Sep 2015 Planned End Date changed from 1 Jan 2016 to 1 May 2016, as reported by ClinicalTrials.gov.